361
Participants
Start Date
May 31, 2008
Primary Completion Date
December 31, 2009
Study Completion Date
December 31, 2009
Lixisenatide (AVE0010)
Self administered by subcutaneous injections once daily within the hour preceding breakfast.
Placebo
Self administered by subcutaneous injections once daily within the hour preceding breakfast.
Pen auto-injector
Sanofi-Aventis Administrative Office, Bridgewater
Sanofi-Aventis Administrative Office, Diegem
Sanofi-Aventis Administrative Office, Mumbai
Sanofi-Aventis Administrative Office, Netanya
Sanofi-Aventis Administrative Office, Tokyo
Sanofi-Aventis Administrative Office, México
Sanofi-Aventis Administrative Office, Warsaw
Sanofi-Aventis Administrative Office, Bucharest
Sanofi-Aventis Administrative Office, Moscow
Sanofi-Aventis Administrative Office, Seoul
Sanofi-Aventis Administrative Office, Mégrine
Sanofi-Aventis Administrative Office, Kiev
Lead Sponsor
Sanofi
INDUSTRY